Funder
National Research Foundation of Korea
Retina Research Foundation
Publisher
Springer Science and Business Media LLC
Reference102 articles.
1. Abbey AM, Patel SS, Barakat M, Hershberger VS, Bridges WZ, Eichenbaum DA, Lally D, Storey PP, Roy M, Duker JS (2023) The DAVIO trial: a phase 1, open-label, dose-escalation study of a single injection of EYP-1901 (vorolanib in Durasert® platform) demonstrating reduced treatment burden in wet age-related macular degeneration. Invest Ophthalmol vis Sci 64(8):931–931
2. Adamis AP, Shima DT (2005) The role of vascular endothelial growth factor in ocular health and disease. Retina 25(2):111–118. https://doi.org/10.1097/00006982-200502000-00001
3. Adams CM, Anderson K, Artman G 3rd, Bizec JC, Cepeda R, Elliott J, Fassbender E, Ghosh M, Hanks S, Hardegger LA, Hosagrahara VP, Jaffee B, Jendza K, Ji N, Johnson L, Lee W, Liu D, Liu F, Long D, Ma F, Mainolfi N, Meredith EL, Miranda K, Peng Y, Poor S, Powers J, Qiu Y, Rao C, Shen S, Sivak JM, Solovay C, Tarsa P, Woolfenden A, Zhang C, Zhang Y (2018) The discovery of N-(1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6-((methylamino)methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide (acrizanib), a VEGFR-2 inhibitor specifically designed for topical ocular delivery, as a therapy for neovascular age-related macular degeneration. J Med Chem 61(4):1622–1635. https://doi.org/10.1021/acs.jmedchem.7b01731
4. Askew BC, Furuya T, Edwards DS (2018) Ocular distribution and pharmacodynamics of SF0166, a topically administered αvβ3 integrin antagonist, for the treatment of retinal diseases. J Pharmacol Exp Ther 366(2):244–250. https://doi.org/10.1124/jpet.118.248427
5. Atomwise AIMS Program (2024) AI is a viable alternative to high throughput screening: a 318-target study. Sci Rep 14(1):7526. https://doi.org/10.1038/s41598-024-54655-z